Business

Mass. Movers

FDA report lifts Aegerion drug

istockphoto.com

Aegerion Pharmaceuticals Inc. shares jumped Monday after Food and Drug Administration medical reviewers said the Cambridge firm’s proposed drug to treat a rare genetic disorder that causes high cholesterol is effective at reducing it, but there is a potential to cause liver damage. The drug, lomitapide, will be reviewed on Wednesday by a panel of non-FDA medical specialists, which will make recommendations to the agency about whether lomitapide should be approved.

Advertisement